The Personal Care Products Council expects at least three cosmetics reform bills to make reappearances in the 115th Congress, but the best opportunity for updating regulations may involve tacking related provisions onto must-pass FDA user-fee bills this year. Top execs discussed the current legislative landscape during the “Washington Report” session of the trade group’s annual meeting in Palm Beach, Fla.
The cosmetics industry is “closer than we have ever been” in its efforts to modernize the US regulatory framework for cosmetics, but in the current political climate the best chance for reform may not be standalone cosmetics legislation, according to Personal Care Products Council leadership.
Rather, FDA user-fee legislation currently under development could be “our big shot” for updating cosmetics regulations, PCPC’s John Hurson, executive...
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
Legislator education is key to checking state bills that overreach, says Ross, executive VP of government affairs at the Personal Care Products Council, discussing the rising tide of US state bills aimed at restricting ingredient use.
FDA reminds companies which registered with agency solely to manufacture OTC sanitizers during COVID-19 public health emergency they will be subject to FY2025 OTC monograph user fees if they don’t delist and deregister as monograph drug manufacturers by 12 a.m. on 31 December.
With monographs@FDA portal down, agency moves to NextGen and extends comment period through 27 September for first OTC monograph change it proposed using its overhauled program other than 32 monographs finalizations required in 2020 legislation authorizing overhaul.
OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
